|
6 Companies |
|
9 Products |
|
9 Products |
|
11 Mechanisms of Action |
|
0 Trials |
|
51 News |
|
| 12» |
- | Trial completion, Trial completion date, Surgery: Rhinological Outcomes in Endonasal Pituitary Surgery (clinicaltrials.gov) - Aug 22, 2018
P=N/A, N=235, Completed, Sponsor: St. Joseph's Hospital and Medical Center, Phoenix
Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Dec 2015
- | Signifor LAR (pasireotide long acting release) / Recordati
Trial completion date, Trial primary completion date: Passion I: Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma. (clinicaltrials.gov) - Aug 10, 2018
P2, N=20, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Dec 2015 Trial completion date: May 2016 --> Sep 2017 | Trial primary completion date: May 2016 --> Sep 2017
- | Trial completion date: Effects of Hormone Stimulation on Brain Scans for Cushing s Disease (clinicaltrials.gov) - Jun 14, 2018
P1, N=30, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Trial completion date: May 2016 --> Sep 2017 | Trial primary completion date: May 2016 --> Sep 2017 Trial completion date: Jan 2018 --> Jun 2018
- || Signifor LAR (pasireotide long acting release) / Recordati
Trial completion: Passion I: Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma. (clinicaltrials.gov) - Jun 2, 2018
P2, N=20, Completed, Sponsor: Novartis Pharmaceuticals
Trial completion date: Jan 2018 --> Jun 2018 Recruiting --> Completed
- | Trial completion, Trial primary completion date: Effects of Hormone Stimulation on Brain Scans for Cushing s Disease (clinicaltrials.gov) - Feb 1, 2018
P1, N=28, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting --> Completed Recruiting --> Completed | Trial primary completion date: May 2018 --> Jan 2018
- | hydrocortisone / Generic mfg., dexamethasone injection / Generic mfg.
Trial completion: Peri-Operative Steroid Management in Patients (clinicaltrials.gov) - May 17, 2017
P=N/A, N=51, Completed, Sponsor: Washington University School of Medicine
Recruiting --> Completed | Trial primary completion date: May 2018 --> Jan 2018 Active, not recruiting --> Completed
- | Phase classification: Effects of Hormone Stimulation on Brain Scans for Cushing s Disease (clinicaltrials.gov) - Apr 19, 2017
P, N=30, Recruiting, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Active, not recruiting --> Completed Phase classification: P=N/A --> P
- Trial completion, Trial primary completion date: PITUIGENE: Identification of GENEtic Markers of Aggressiveness and Malignancy by Array Comparative Genomic Hybrization Analysis (CGH) (clinicaltrials.gov) - Jan 23, 2017
P=N/A, N=213, Completed, Sponsor: Hospices Civils de Lyon
Phase classification: P=N/A --> P Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Jan 2017
- Signifor LAR (pasireotide long acting release) / Recordati
Trial primary completion date: Passion I: Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma. (clinicaltrials.gov) - Jan 4, 2017
P2, N=23, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Jan 2017 Trial primary completion date: Dec 2016 --> Sep 2017
- Trial primary completion date, Surgery: Rhinological Outcomes in Endonasal Pituitary Surgery (clinicaltrials.gov) - Oct 12, 2016
P=N/A, N=200, Active, not recruiting, Sponsor: St. Joseph's Hospital and Medical Center, Phoenix
Trial primary completion date: Dec 2016 --> Sep 2017 Trial primary completion date: Sep 2016 --> Sep 2017
- Trial primary completion date, Surgery: Rhinological Outcomes in Endonasal Pituitary Surgery (clinicaltrials.gov) - Jun 23, 2016
P=N/A, N=200, Active, not recruiting, Sponsor: St. Joseph's Hospital and Medical Center, Phoenix
Trial primary completion date: Sep 2016 --> Sep 2017 Trial primary completion date: May 2016 --> Sep 2016
- Trial primary completion date, Surgery: Rhinological Outcomes in Endonasal Pituitary Surgery (clinicaltrials.gov) - Jan 30, 2016
P=N/A, N=200, Active, not recruiting, Sponsor: St. Joseph's Hospital and Medical Center, Phoenix
Trial primary completion date: May 2016 --> Sep 2016 Trial primary completion date: Dec 2015 --> May 2016
- Trial primary completion date: PITUIGENE: Identification of GENEtic Markers of Aggressiveness and Malignancy by Array Comparative Genomic Hybrization Analysis (CGH) (clinicaltrials.gov) - Jan 20, 2016
P=N/A, N=240, Active, not recruiting, Sponsor: Hospices Civils de Lyon
Trial primary completion date: Dec 2015 --> May 2016 Trial primary completion date: Dec 2015 --> Jun 2016
- hydrocortisone / Generic mfg., dexamethasone injection / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date: Peri-Operative Steroid Management in Patients (clinicaltrials.gov) - Dec 10, 2015
P=N/A, N=51, Active, not recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Dec 2015 --> Jun 2016 Recruiting --> Active, not recruiting | N=30 --> 51 | Trial primary completion date: Jun 2015 --> Dec 2016
- | Trial completion, Enrollment change: Neurosurgery Recruitment Maneuver Study (clinicaltrials.gov) - Dec 5, 2015
P=N/A, N=22, Completed, Sponsor: University of British Columbia
Recruiting --> Active, not recruiting | N=30 --> 51 | Trial primary completion date: Jun 2015 --> Dec 2016 Recruiting --> Completed | N=30 --> 22
- Trial primary completion date, Surgery: Rhinological Outcomes in Endonasal Pituitary Surgery (clinicaltrials.gov) - Sep 24, 2015
P=N/A, N=200, Active, not recruiting, Sponsor: St. Joseph's Hospital and Medical Center, Phoenix
Recruiting --> Completed | N=30 --> 22 Trial primary completion date: Jun 2015 --> Dec 2015
- |||| Signifor LAR (pasireotide long acting release) / Recordati
Trial completion: Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin (clinicaltrials.gov) - Sep 18, 2015
P2, N=118, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jun 2015 --> Dec 2015 Active, not recruiting --> Completed
- Enrollment change, Trial termination, Trial primary completion date: PI01: Proton Radiation Therapy for Pituitary Adenoma (clinicaltrials.gov) - Aug 12, 2015
P=N/A, N=16, Terminated, Sponsor: University of Florida
Active, not recruiting --> Completed N=100 --> 16 | Recruiting --> Terminated | Trial primary completion date: Oct 2041 --> Jul 2015; Due to slow enrollment and feasibility issues.
- Enrollment closed: PITUIGENE: Identification of GENEtic Markers of Aggressiveness and Malignancy by Array Comparative Genomic Hybrization Analysis (CGH) (clinicaltrials.gov) - Jun 20, 2015
P=N/A, N=240, Active, not recruiting, Sponsor: Hospices Civils de Lyon
N=100 --> 16 | Recruiting --> Terminated | Trial primary completion date: Oct 2041 --> Jul 2015; Due to slow enrollment and feasibility issues. Recruiting --> Active, not recruiting
- Phase classification: Effects of Hormone Stimulation on Brain Scans for Cushing s Disease (clinicaltrials.gov) - May 19, 2015
P0, N=30, Recruiting, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting --> Active, not recruiting Phase classification: P=N/A --> P0
- Trial primary completion date: Tegaderm and Visual Evoked Potentials (clinicaltrials.gov) - Mar 11, 2015
P=N/A, N=6, Terminated, Sponsor: Rutgers, The State University of New Jersey
Phase classification: P=N/A --> P0 Trial primary completion date: Jan 2015 --> Sep 2014
- Trial primary completion date, Surgery: Rhinological Outcomes in Endonasal Pituitary Surgery (clinicaltrials.gov) - Mar 9, 2015
P=N/A, N=200, Active, not recruiting, Sponsor: St. Joseph's Hospital and Medical Center, Phoenix
Trial primary completion date: Jan 2015 --> Sep 2014 Trial primary completion date: Jan 2014 --> Jun 2015
- hydrocortisone / Generic mfg., dexamethasone injection / Generic mfg.
Trial primary completion date: Peri-Operative Steroid Management in Patients (clinicaltrials.gov) - Dec 10, 2014
P=N/A, N=30, Recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Jan 2014 --> Jun 2015 Trial primary completion date: Dec 2015 --> Jun 2015
- Trial completion, Trial primary completion date: Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors (clinicaltrials.gov) - Dec 6, 2014
P=N/A, N=49, Completed, Sponsor: Emory University
Trial primary completion date: Dec 2015 --> Jun 2015 Active, not recruiting --> Completed | Trial primary completion date: Nov 2014 --> Aug 2014
- ||| Trial completion: Comparison of Surgical Approach to Endoscopic Pituitary Adenoma Resection (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=55, Completed, Sponsor: University of Calgary
Active, not recruiting --> Completed | Trial primary completion date: Nov 2014 --> Aug 2014 Recruiting --> Completed
- Enrollment change, Trial termination: Tegaderm and Visual Evoked Potentials (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=6, Terminated, Sponsor: Rutgers, The State University of New Jersey
Recruiting --> Completed N=40 --> 6 | Recruiting --> Terminated; PI leaving institution
- Enrollment open: Neurosurgery Recruitment Maneuver Study (clinicaltrials.gov) - Sep 22, 2014
P=N/A, N=30, Recruiting, Sponsor: University of British Columbia
N=40 --> 6 | Recruiting --> Terminated; PI leaving institution Not yet recruiting --> Recruiting
- Signifor LAR (pasireotide long acting release) / Recordati
Trial primary completion date: Passion I: Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma. (clinicaltrials.gov) - Jul 18, 2014
P2, N=23, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2014 --> Dec 2016
- || Signifor LAR (pasireotide long acting release) / Recordati
Trial primary completion date: Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin (clinicaltrials.gov) - May 26, 2014
P2, N=118, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Nov 2014 --> Dec 2016 Trial primary completion date: Jan 2014 --> Apr 2015
- || Signifor LAR (pasireotide long acting release) / Recordati
Trial completion date: Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin (clinicaltrials.gov) - May 26, 2014
P2, N=118, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jan 2014 --> Apr 2015 Trial completion date: Jan 2014 --> Apr 2015
- Trial completion: Copeptin as a Diagnostic Marker in the Management of Neurosurgical Patients With Disturbance of Water Homeostasis (clinicaltrials.gov) - May 18, 2014
P=N/A, N=125, Completed, Sponsor: University Hospital, Basel, Switzerland
Trial completion date: Jan 2014 --> Apr 2015 Recruiting --> Completed
- Enrollment change, Surgery: Rhinological Outcomes in Endonasal Pituitary Surgery (clinicaltrials.gov) - Apr 22, 2014
P=N/A, N=200, Active, not recruiting, Sponsor: St. Joseph's Hospital and Medical Center, Phoenix
Recruiting --> Completed N=300 --> 200
- Enrollment closed, Surgery: Rhinological Outcomes in Endonasal Pituitary Surgery (clinicaltrials.gov) - Apr 22, 2014
P=N/A, N=200, Active, not recruiting, Sponsor: St. Joseph's Hospital and Medical Center, Phoenix
N=300 --> 200 Enrolling by invitation --> Active, not recruiting
- Enrollment open: Tegaderm and Visual Evoked Potentials (clinicaltrials.gov) - Apr 1, 2014
P=N/A, N=40, Recruiting, Sponsor: Rutgers, The State University of New Jersey
Enrolling by invitation --> Active, not recruiting Not yet recruiting --> Recruiting
- Surgery: Neurosurgery Recruitment Maneuver Study (clinicaltrials.gov) - Mar 18, 2014
P=N/A, N=30, Not yet recruiting, Sponsor: University of British Columbia
- hydrocortisone / Generic mfg.
Clinical: Peri-Operative Steroid Management in Patients (clinicaltrials.gov) - Mar 9, 2014
P=N/A, N=30, Recruiting, Sponsor: Washington University School of Medicine
- | NN1213 / Novo Nordisk
Trial completion: Evaluation of Factors in Human Brain Tumors (clinicaltrials.gov) - Feb 19, 2014
P=N/A, N=800, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Not yet recruiting --> Recruiting No longer recruiting --> Completed
- Trial completion: Barrow Nasal Inventory Survey (clinicaltrials.gov) - Dec 8, 2013
P=N/A, N=94, Completed, Sponsor: St. Joseph's Hospital and Medical Center, Phoenix
No longer recruiting --> Completed Active, not recruiting --> Completed
- Enrollment closed: Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors (clinicaltrials.gov) - Dec 1, 2013
P=N/A, N=44, Active, not recruiting, Sponsor: Emory University
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Enrollment open: PITUIGENE: Identification of GENEtic Markers of Aggressiveness and Malignancy by Array Comparative Genomic Hybrization Analysis (CGH) (clinicaltrials.gov) - Oct 9, 2013
P=N/A, N=240, Recruiting, Sponsor: Hospices Civils de Lyon
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Signifor LAR (pasireotide long acting release) / Recordati
Trial initiation date: Passion I: Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma. (clinicaltrials.gov) - May 22, 2013
P2, N=23, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Initiation date: Apr 2012 --> Nov 2012
- RG4733 / Roche
Trial termination: Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia (clinicaltrials.gov) - Apr 30, 2013
P1/2, N=129, Terminated, Sponsor: National Cancer Institute (NCI)
Initiation date: Apr 2012 --> Nov 2012 Active, not recruiting --> Terminated
- ||| Signifor LAR (pasireotide long acting release) / Recordati
Enrollment closed: Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin (clinicaltrials.gov) - Apr 15, 2013
P2, N=118, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Terminated Recruiting --> Active, not recruiting
- Trial initiation date: PI01: Proton Radiation Therapy for Pituitary Adenoma (clinicaltrials.gov) - Mar 10, 2013
P=N/A, N=100, Recruiting, Sponsor: University of Florida
Recruiting --> Active, not recruiting Initiation date: Jul 2007 --> Oct 2007
- | Signifor LAR (pasireotide long acting release) / Recordati
Enrollment open: Passion I: Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma. (clinicaltrials.gov) - Oct 16, 2012
P2, N=23, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Jul 2007 --> Oct 2007 Not yet recruiting --> Recruiting
- | New P2 trial: Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors (clinicaltrials.gov) - Sep 19, 2012
P2, N=40, Completed, Sponsor: Endocyte
- | Sufenta (sufentanil) / Akorn
Enrollment change: Anaesthesia for Supratentorial Tumor Resection (clinicaltrials.gov) - Jul 5, 2012
P3, N=69, Completed, Sponsor: Assistance Publique - H
Not yet recruiting --> Recruiting N=100 --> 69
- Signifor (pasireotide) / Recordati
New P2/3 trial: Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas (clinicaltrials.gov) - Jun 13, 2012
P2/3, N=30, Recruiting, Sponsor: Federal University of Rio de Janeiro
- Trial completion: Scalp Nerve Blocks for Post-Craniotomy Pain (clinicaltrials.gov) - Feb 28, 2012
P=N/A, N=89, Completed, Sponsor: St. Michael's Hospital, Toronto
N=100 --> 69 Recruiting --> Completed
- farletuzumab (MORAB-003) / Eisai
Enrollment change: MORAb-003-007: Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas (clinicaltrials.gov) - Dec 6, 2011
P2, N=0, Withdrawn, Sponsor: Morphotek
Recruiting --> Completed N=30 --> 0